Metal-Binding Peptide Targeting for Intracellular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical treatments for chronic inflammatory diseases, such as cancer and diabetes, face challenges in effectively targeting metastatic cells and addressing the complexity of biochemical dysfunctions, leading to limited efficacy and significant side effects, while existing delivery mechanisms for therapeutic peptides are inadequate.
Innovation Solution
The development of metal-binding domain (MBD) peptides that can selectively target and deliver therapeutic agents to intracellular molecular targets, such as PRR5D, NF-kappa-B, and HSP regulators, enhancing the efficacy of existing treatments by facilitating cellular uptake and nuclear localization, and the use of adaptive signatures to identify suitable therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used to treat chronic inflammatory diseases, then the treatment covers broad disease areas, but the efficacy is limited and side effects are significant
Solution Approach 1:
The patent segments the therapeutic approach by dividing it into two distinct components: a targeting moiety that directs the agent to specific cells or tissues, and a therapeutic moiety that delivers the actual treatment. This segmentation allows the therapeutic agent to be precisely delivered only where needed, improving efficacy while reducing exposure of healthy tissues to harmful effects.
Solution Approach 2:
The patent implements local quality by creating heterogeneity in drug distribution through the targeting moiety. Instead of uniform distribution throughout the body, the therapeutic agent is concentrated specifically in target cells or tissues that express particular surface markers or receptors. This localized delivery enhances treatment efficacy at the disease site while minimizing side effects in healthy tissues.
2Reliability
If existing delivery mechanisms are used for therapeutic peptides, then the administration is simple, but the delivery to intracellular targets is inadequate
Solution Approach 1:
The patent introduces a targeting moiety as an intermediary component that mediates between the therapeutic peptide and the intracellular target. This targeting moiety acts as a bridge that recognizes specific surface markers on target cells and facilitates the entry of the therapeutic peptide into the cell, enabling intracellular delivery without requiring complex delivery devices or procedures.
Solution Approach 2:
The patent creates a composite therapeutic agent by combining the targeting moiety and therapeutic moiety into a single conjugate or complex. This composite structure integrates the cell-targeting capability with the therapeutic function, allowing the peptide to both locate and enter target cells effectively while maintaining relative simplicity in administration.
3Measurement precision
If non-specific therapeutic agents are administered, then the treatment approach is simple, but the ability to target metastatic cells is poor
Solution Approach 1:
The patent segments the therapeutic agent into a targeting moiety responsible for precise localization and a therapeutic moiety responsible for treatment. The targeting moiety is designed to recognize and bind to specific surface markers or receptors that are overexpressed on metastatic cells, enabling precise targeting without requiring complex imaging or guidance systems.
Solution Approach 2:
The patent achieves local quality by designing the targeting moiety to confer specificity on the therapeutic agent. Different targeting moieties can be developed for different disease types or metastatic locations, allowing precise targeting of specific cell populations while leaving other tissues unaffected. This molecular level specificity eliminates the need for complex external targeting systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MBD peptides improve the delivery and efficacy of therapeutic agents to cancer cells and diabetic tissues, potentially increasing treatment success rates and reducing side effects by targeting specific molecular pathways and cellular stress responses.
Implementation Method 1
metal-binding domain (MBD) peptides that can selectively target and deliver therapeutic agents to intracellular molecular targets
Implementation Method 2
enhancing the efficacy of existing treatments by facilitating cellular uptake and nuclear localization
Data Source
AI summary
The present invention is related methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes.